Natixis Advisors LLC boosted its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 3.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,842,646 shares of the company's stock after purchasing an additional 69,683 shares during the period. Natixis Advisors LLC owned approximately 0.10% of Kenvue worth $39,341,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in KVUE. FMR LLC increased its stake in shares of Kenvue by 2.3% in the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company's stock worth $3,189,985,000 after purchasing an additional 3,075,019 shares in the last quarter. State Street Corp increased its stake in Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after buying an additional 18,283,473 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company's stock worth $2,011,832,000 after buying an additional 7,115,374 shares in the last quarter. Geode Capital Management LLC increased its stake in Kenvue by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company's stock worth $1,029,810,000 after buying an additional 399,846 shares in the last quarter. Finally, Harris Associates L P increased its stake in Kenvue by 7.5% in the 3rd quarter. Harris Associates L P now owns 31,459,511 shares of the company's stock worth $727,658,000 after buying an additional 2,186,114 shares in the last quarter. Institutional investors own 97.64% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft lowered Kenvue from a "buy" rating to a "hold" rating and cut their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. UBS Group lowered their price target on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Citigroup decreased their price objective on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research note on Wednesday, January 15th. Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Finally, Piper Sandler raised their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Kenvue has a consensus rating of "Hold" and an average target price of $23.75.
View Our Latest Analysis on KVUE
Kenvue Stock Down 0.5 %
Shares of NYSE:KVUE traded down $0.12 during trading hours on Thursday, reaching $23.41. The stock had a trading volume of 16,377,533 shares, compared to its average volume of 16,076,434. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm's 50 day moving average is $21.98 and its 200-day moving average is $22.42. The stock has a market capitalization of $44.74 billion, a price-to-earnings ratio of 44.17, a P/E/G ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46.
Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.50%. The ex-dividend date was Wednesday, February 12th. Kenvue's dividend payout ratio (DPR) is 154.72%.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
